Figure 1: Progression-free Survival gBRCAmut Cohort




Figure 2: Progression-free Survival Non-gBRCA – HRD positive




Figure 3: Progression-free Survival Non-gBRCA overall




Figure 4: Progression-free Survival Non-gBRCA – HRD negative




Figure 5: Progression-free Survival
Combined Study Population
(2 cohorts combined-gBRCAmut and non-gBRCAmut)




Figure 6: Progression-Free Survival in the HRDpos/BRCAwt Subgroup of the Non-gBRCAmut Cohort




Figure 7: Kaplan-Meier Plot for Progression-Free Survival in the HRDpos/Somatic BRCAmut Subgroup of the Non-gBRCAmut Cohort






Figure 8: Mean Change from Baseline (±SE) for Platelets Over Time: All Patients Cohort



Note: the data are displayed weekly for Cycle 1 and then every cycle (every 4 weeks) thereafter.

Figure 9: Kaplan-Meier Plot for Progression-Free Survival in the gBRCAmut Cohort Based on IRC Assessment by Niraparib Dose Administered for the Longest Duration (Niraparib Patients in the Safety Population)






Figure 10: Kaplan-Meier Plot for Progression-Free Survival in the Non-gBRCAmut Cohort Based on IRC Assessment by Niraparib Dose Administered for the Longest Duration (Niraparib Patients in the Safety Population)

Figure 11: Secondary Endpoints in the Primary Efficacy Populations.

	gBRCAmut		non-gBRCAmut HRDpositive		non-gBRCAmut Overall	
Endpoint	Niraparib (N=138)	Placebo (N=65)	Niraparib (N=106)	Placebo (N=56)	Niraparib (N=234)	Placebo (N=116)
Chemotherapy-free interval						
Median (95% CI) — mo	22.8 (17.9, NR)	9.4 (7.9, 10.6)	18.2 (14.2, 24.3)	7.7 (6.3, 10.6)	12.7 (11.0, 14.7)	8.6 (6.9, 10.0)
P value	<0.0001		<0.0001		<0.0001	
Hazard ratio (95% CI)	0.26 (0.169, 0.414)		0.31 (0.190, 0.493)		0.50 (0.370, 0.666)	
Time to first subsequent therapy						
Median (95% CI) — mo	21.0 (17.5, NR)	8.4 (6.6, 10.6)	15.9 (12.4, NR)	6.0 (4.7, 9.8)	11.8 (9.9, 13.1)	7.2 (5.7, 8.5)
P value	<0.0001		<0.0001		<0.0001	
Hazard ratio (95% CI)	0.31 (0.205, 0.481)		0.36 (0.232, 0.565)		0.54 (0.411, 0.719)	
Progression-free survival 2						
Median (95% CI) — mo	25.8 (20.3, NR)	16.0 (10.8, 21.9)	22.3 (18.6, NR)	17.6 (11.8, NR)	18.4 (16.0, 21.1)	15.1 (12.2, 20.3)
P value	0.0005		0.0472		0.0078	
Hazard ratio (95% CI)	0.41 (0.242, 0.687)		0.58 (0.340, 0.999)		0.64 (0.465, 0.892)	

Figure 12A. Analysis of Progression-Free Survival in the g*BRCA*mut Cohort

(A)




Figure 12B. Analysis of Progression-Free Survival in the non-g*BRCA*mut, HRDpos Subgroup




Figure 12C. Analysis of Progression-Free Survival in the overall non-g*BRCA*mut Cohort.

(C)




Figure 13. Analysis of Chemotherapy-Free Survival Interval in gBRCA^{mut} and non-gBRCA^{mut} cohorts




Figure 14. Analysis of Time to First Subsequent Treatment in gBRCA^{mut} and non-gBRCA^{mut} cohorts




Figure 15. Analysis of Efficacy of Next-Line Treatment in pooled gBRCA^{mut} and non-gBRCA^{mut} cohorts





Figure 16. Estimated Probability of PD at 6 Months After the Last Dose of Platinum-Based Therapy






Figure 17. Number of Lines of Platinum-Based Chemotherapy in the (A) gBRCAmut and (B) non-gBRCAmut Cohorts and Total Chemotherapy in the (C) gBRCAmut and (D) non-gBRCAmut cohorts (Placebo Arm)

Figure 18. Patient-Reported Outcomes were similar for niraparib and placebo

